HIV and hepatitis C co-infection.
HIV/HCV co-infection is emerging as a major cause of morbidity and mortality in the 21st century. This editorial reviews the prevalence of co-infection, the factors involved in acquisition of HCV, and the influence of co-infection on disease progression. We examine the results of the major co-infection trials including APRICOT, ACTG 5071 and RIBAVIC. These trials, in association with emerging evidence for future therapies currently undergoing investigation, have led to increased hope of treatment success in co-infected individuals.
Jones
R
R
Department of HIV and GU Medicine, The Chelsea and Westminster Hospital, London, UK.
Dunning
J
J
Nelson
M
M
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy / Q000635:transmission / Q000821:virology*; D006801:Humans; D008099:Liver / Q000821:virology; D016032:Randomized Controlled Trials as Topic
D019380:Anti-HIV Agents; D000998:Antiviral Agents